Deferasirox (Exjade, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia. - Greenberg,P.; Dine,G.; Ganser,A.; Verhoef,G.; DeBusscher,L.; Quarta,G.; Zache,P.; Alimena,G.; Jeng,M.; Tchernia,G.; Gathmann,I.; Alberti,D.; et al. (Blood, 2005)